INTERVENTIONAL VASCULAR CORPORATE PRESS RELEASES

Please find below a list of our press releases.

27 Feb 2017

BTG Receives U.S. FDA 510(k) Clearance for EKOS (R) Control Unit 4.0

BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS® Control Unit 4.0.

9 Jan 2017

First Pulmonary Embolism Patients in Hong Kong Treated with the EKO...

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system.

9 Jul 2015

Randomized Controlled Multi-Center Trial

EKOS Corporation, a privately held medical device company located in Bothell, Washington, announced the results of DUET, the world’s first and only multicenter randomized trial that compares ultrasound-accelerated, catheter-directed thrombolysis (USAT) to standard side-hole catheter-directed thrombolysis (CDT) for the treatment of acute peripheral arterial thrombotic occlusions

11 Jun 2014

EKOS™ Initiates a Pivotal New Study

ACCESS PTS study aims to evaluate the safety and efficacy of Ultrasound Accelerated Thrombolysis with standard thrombolytic infusion for treatment of Post-Thrombotic Syndrome

23 May 2014

EkoSonic™ Endovascular System

EkoSonic™ Endovascular System receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA

30 Mar 2014

Acute Pulmonary Embolism Trial Confirms Safety and Efficacy of Ultr...

EKOS Corporation, a BTG International group company (BTG plc (LSE: BTG)), notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.